Dobutamine hydrochloride is an effective parenteral inotropic agent for the acute treatment of congestive heart failure.'-" Although tachyphylaxis has been shown to occur with prolonged infusions,", 7 sustained improvement in functional class, left ventricular function, and exercise tolerance has been demonstrated after 72-hour infusions.8-1' Intermittent, outpatient therapy with dobutamine has recently been suggested for long-term inotropic support.1",13 In this study, 13 patients with severe congestive heart failure were treated with intermittent ambulatory outpatient 48-hour dobutamine infusions and were then followed for up to 6 months.
METHODS

Patients.
Thirteen ambulatory patients, mean age 62 2 11 years, with New York Heart Association class III or IV heart failure, were studied. Their clinical characteristics are summarized in Table I . Patients were excluded if they had surgically correctable heart disease, myocardial infarction within 3 months, an associated terminal or incapacitating medical illness, exercise-induced angina pectoris, or ventricular tachycardia (>:3 beats) on a 24-hour continuous ECG recording. This study was approved by the institutional committees on human research. Informed consent was obtained from each patient.
Study
protocol.
Patients were hospit,alized and stabilized on standard medical therapy. Radionuclide ventriculography was then performed with a conventional gamma camera (General Electric Data, Milwaukee, Wise.) equipped with an all-purpose high sensitivity, low-energy, parallel-hole collimator interfaced to a portable cardiac imaging computer (Medical Data Systems, Ann Arbor, Mich.). Acquisitions were performed in the lo-degree right anterior oblique, 45-degree left anterior oblique, and left lateral projections. Global left. ventricular ejection fraction was calculated using a variable region-of-interest software program.
Patients then underwent right heart catheterization with a No. 7F triple-lumen pulmonary artery thermodilution catheter (American Edwards Corp., Santa Ana, Calif.). After a SO-minute stabilization period, heart rate, blood pressure, pulmonary wedge pressure, and cardiac output were measured. Dobutamine infusion was then begun at 2.5 pg/kg/min. The dose was increased to 5.0,7.5, 10.0, and 15.0 pg/kg/min at 20-minute intervals. Hemodynamic measurements were repeated at each stage.
Afterwards, a subcutaneous infusion port system (MediPort, Cormed Inc., Medina, N.Y.) was implanted in the subclavicular fossa. The tip of the catheter attached to the port was inserted via the cephalic or subc*lavian vein to the 787 IV  IV  III  III  III  IV  III  IV  IV  IV  IV  IV  IV Abbreviations: Al = aldactone; Am = amiodarone; C = captopril; D = digoxin; F = furosemide; H = hydralazine; M = metolazone; N = nitrates; NYHA = New York Heart Association; Q = quinidine. junction of the right atrium and the superior vena cava. The dobutamine dose that gave the maximum cardiac output without inducing significant ventricular ectopy, a 10 mm Hg rise in systolic blood pressure, a 10 bpm rise in heart rate, or other side effects was chosen for intermittent chronic infusion.
Long-term follow-up.
After hospital discharge, patients received weekly, 48-hour infusions of dobutamine hydrochloride diluted to a total volume of 60 cc in normal saline. Solutions were infused via a right-angle Huber needle connected to an infusion pump (Cormed Inc., Medina, N.Y.) by standard extension tubing. Patients returned to the chronic twice weekly to have their infusions initiated and discontinued. After discontinuing the infusion, the port was flushed once with 5 cc of heparinized saline. Further care was not required until the next infusion. No change in concurrent medications occurred during the study period.
Statistical
analysis.
Dobutamine titration hemodynamic data are given as mean + standard deviation. The paired t test was used to compare each dose with the zero dose, with an exeriment-wise alpha error of 5% using the Bonferroni multiple comparison method. A p value <O.Ol was considered significant.
RESULTS
Acute hemodynamic
data. Baseline hemodynamic data before dobutamine titration are detailed in Table II . The individual hemodynamic responses to a 10 bg/kg/min infusion of dobutamine are depicted in Fig. 1 . The mean acute hemodynamic responses to dobutamine titration are summarized in Table III . Although the trend was for increasing dobutamine infusion rates to increase heart rate and mean arterial pressure and to decrease pulmonary wedge pressure, the changes were statistically insignificant. Significant improvements in cardiac index and sys- ('I = cardiac index; HR = heart rate: MAP = mean arterial p~rs~urr; PM'I' = pulmonary wedge prrwm~:
S,\ ,i := <vsirmir vahv!ili+r resistance. *p, < O.l)l vs. baseline. tD < 0.001 vs basel i ne temic vascular resistance were found at infusion rates ~2.5 pg/kg/min. All patients achieved at least a 25% increase in cardiac output on the dose that was subsequently chosen for the chronic infusion rate. This dose averaged 7.5 r*g/kg/min for the group. Follow-up and mortality (Table IV) . Symptomatic improvement was achieved in 7 of 13 (54% ) patients. Four improved by one functional class, two improved by two classes, and one improved by three classes. Nevertheless, only three patients (Nos. 3, 5, and 13) survived the 26-week study period. Two of the surviving patients were the only patients in the group treated with amiodarone.
Sudden death occurred in six patients, three died of progressive heart failure, and one died from pulmonary embolism. Three of the deaths occurred during the weekly 48-hour infusion period: one patient died suddenly, while two died in cardiogenic shock. of dobutamine to provide chronic inotropic support in heart failure patients prompted us to pursue this mode of therapy in our patients. However, the results of the present study show that although 13 of 13 (100%) patients had initial hemodynamic improvement and 7 of 13 (54%) patients had symptomatic improvement, eight (62%) died within 3 months of starting therapy and 10 of 13 (77 % ) were dead after 6 months.
One explanation for the more negative results in the present study than in those previously reported is that our patients were more hemodynamically compromised (mean ejection fraction 16%) mean cardiac index 1.6 L/min/m2, mean pulmonary artery wedge pressure 24 mm Hg, mean systemic vascular resistance 1925 dynes . s . cmm5) and thus had more severe heart failure and a worse prognosis. Patients in Unverferth's series9 had a mean ejection fraction of 25% and a mean cardiac index of 2.0 L/mm/m? 8 of 37 (22%) patients were dead at 10 weeks, though 17 of 30 (57%) patients were dead at 10 months. Only 2 of 17 (12 % ) patients reported by Leier et all2 were dead at 6 months, but their baseline cardiac index was 2.5 L/min/m2.
Applefeld et a1.13 successfully treated two patients for 6 months in a protocol similar to ours, but baseline cardiac indexes were 2.3 and 2.7 L/min/m2, and baseline pulmonary artery wedge pressures were only 8 and 13 mm Hg. Support for the suggestion that the high mortality in our patients was due to the fact that they had more severe disease than did patients in previous studies of dobutamine therapy exists in the work by Maskin et a1.17 They did not find an improvement in exercise tolerance in their patients treated with dobutamine, as did Liang et al." and Leier et a1.12 Mean baseline cardiac index, as in our patients, was 1.6 L/min/m*. Similarly, Weber et al.18 have experienced a 70% mortality over 3 to 5 months in patients with severe heart failure referred to them for investigational inotropic drug therapy. Finally, it should be noted that two of the three survivors in the present study had the lowest pulmonary wedge pressures in the group.
Another possible explanation for the early mortality in our patients is that dobutamine contributed to the six sudden deaths by precipitating malignant ventricular arrhythmias.
Although increased ventricular ectopy is a recognized complication of acute inotropic drug infusions,1g*20 no change in ventricular ectopy was noted during the initial dobutamine infusions in this study. Of interest in this regard is the fact that two of our three survivors were being treated with amiodarone. None of the patients who died received amiodarone therapy. While the role of October, 1986 American Heart Journal antiarrhythmic therapy in reducing mortality in patients with severe heart failure is uncertain, it should be pointed out that sudden death is relatively frequent in these patients and that digitalis, or other newer inotropic agents, may increase myocardial oxygen demands and hence predispose to ventricular arrhythmias and sudden death. The relatively high mortality and incidence of sudden death reported with inotropic agents such as milrinone in patients with severe heart failure raises the possibility that to be effective, these agents will have to be administered in conjunction with antiarrhythmic therapy.
In conclusion, our data suggest that chronic intermittent ambulatory dobutamine infusions are only partly successful in improving symptoms and probably do not prolong survival in patients with severe congestive heart failure. Administration of this form of therapy on a clinical basis should be undertaken cautiously until safety and efficacy are demonstrated in prospective, controlled trials. Whether additional interventions, such as amiodarone therapy, or earlier intervention with intermittent dobutamine infusions or other inotropic agents before end-stage heart failure develops, can benefit patients with severe heart failure remains to be determined. 
